LEP Biomedical
LEP Biomedical have developed a flexible platform technology (HyaGuard™) that effectively delivers anti-inflammatory drugs to the eye following surgeries instead of traditional eye-drops. This simultaneously improves patient quality of life and reduces complications and repeat surgeries.
LEP Biomedical is focused on the glaucoma post-op market due to its long-standing need for such a solution and its market size (>500k procedures performed per year) – 80 million people worldwide with glaucoma. In the US and EU, the cost of glaucoma induced vision loss is $10bn+. LEP Biomedical’s product offers controlled anti-inflammatory release, to reduce post-operative inflammation and scarring in glaucoma patients. HyaGuard™ is a companion product for moderate-refractory drainage surgeries and is positioned as a first mover in post-op care for glaucoma surgeries, with the potential to disrupt the current standard of care and improve patient outcomes.
Key features of HyaGuard™
- Easily inserted under the conjunctiva (<30 sec)
- Biodegradable
- Not externally visible
- No drops required for the patient
- Simple and rapid insertion for the surgeon; value add to many surgeries
- Reduced failures, reoperations and rescues for the healthcare provider
Promoters
- Dr Alan Hibbitts, CEO/Academic Founder
- Prof. Colm O’Brien, CMO/Co-Founder
Current status
- Completed EI Commercialisation Fund
- Patent filed
- In vivo proof of concept
- EI pre-seed start fund investment 2024
Next steps
Seeking seed round of €4.7m which will be used for:
- Regulatory: RFD/CTA/IND. work
- Clinical trials: Pre-clinical -> First in human
- Reimbursement
- IP filings
- GMP manufacture